FRANKLIN
LAKES, N.J., Feb. 27,
2024 /PRNewswire/ -- BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company,
announced today that Dave Hickey has
informed the company of his intent to retire from BD, effective
July 1.
Hickey is currently executive vice president and president of
the Life Sciences segment for BD, a position he has held since
January 2021. Prior to his current
role, Hickey was president of Integrated Diagnostic Solutions from
2019 to 2021, and president of Diagnostic Systems prior to that.
Before joining BD in 2014, Hickey served in a range of executive
leadership positions at Siemens Healthcare.
"For over a decade at BD, Dave has demonstrated a strong,
strategic and innovative approach, empowering his teams to deliver
impactful results through a growth mindset and developing
incredible talent and next-gen leaders at BD," said Tom Polen, chairman, CEO and president of BD. "I
want to express BD's sincere gratitude to Dave for his significant
contributions to BD, especially during the COVID-19 pandemic, where
he led the BD effort to develop numerous rapid and molecular
diagnostic tests in record time to support health care providers
and patients around the world. We wish him all the best in his
well-deserved retirement."
BD intends to name a successor to Hickey prior to his retirement
date.
"Throughout my career, I've been most driven by the people I
have had the privilege to lead, and the important work we've done
to help patients around the world," Hickey said. "In my 10 years at
BD, I've worked alongside some of the most incredible and talented
teams in MedTech who have delivered countless research and
diagnostic innovations, and who are having a profound impact on
people around the world. I'm incredibly proud of what we've
accomplished together and am confident in the continued success of
BD now and in the future."
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its more than
70,000 employees have a passion and commitment to help enhance the
safety and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please
visit bd.com or connect with us on LinkedIn at
www.linkedin.com/company/bd1/, X (formerly
Twitter) @BDandCo or
Instagram @becton_dickinson.
Contacts:
Media:
|
Investors:
|
Troy
Kirkpatrick
|
Adam Reiffe
|
VP, Public
Relations
|
Sr. Director, Investor
Relations
|
858.617.2361
|
201.847.6927
|
troy.kirkpatrick@bd.com
|
adam.reiffe@bd.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dave-hickey-announces-intent-to-retire-from-bd-302071867.html
SOURCE BD (Becton, Dickinson and Company)